Karyopharm Appoints New Chief Medical Officer
Ticker: KPTI · Form: 8-K · Filed: Aug 29, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, management-change
Related Tickers: KPTI
TL;DR
Karyopharm names Dr. O'Malley as new CMO, effective Aug 26.
AI Summary
Karyopharm Therapeutics Inc. announced on August 26, 2024, the appointment of Dr. John J. O'Malley as Chief Medical Officer, effective immediately. Dr. O'Malley previously served as Senior Vice President and Head of Clinical Development at the company. This change is part of the company's ongoing efforts to advance its pipeline.
Why It Matters
The appointment of a new Chief Medical Officer can signal a shift in the company's strategic direction for drug development and clinical trials.
Risk Assessment
Risk Level: low — This filing reports a routine executive appointment, which typically carries low immediate risk.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- Dr. John J. O'Malley (person) — Appointed Chief Medical Officer
- August 26, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Karyopharm Therapeutics Inc.?
Dr. John J. O'Malley has been appointed as the new Chief Medical Officer.
When was the appointment of the new Chief Medical Officer effective?
The appointment was effective August 26, 2024.
What was Dr. John J. O'Malley's previous role at Karyopharm Therapeutics Inc.?
Dr. O'Malley previously served as Senior Vice President and Head of Clinical Development.
What is the principal executive office address for Karyopharm Therapeutics Inc.?
The principal executive office is located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 808 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2024-08-29 16:05:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
- $100,000 — rrangement"): (i) a lump sum payment of $100,000, payable on November 6, 2024 and (ii) t
Filing Documents
- d883504d8k.htm (8-K) — 27KB
- d883504dex101.htm (EX-10.1) — 77KB
- d883504dex102.htm (EX-10.2) — 36KB
- 0001193125-24-209907.txt ( ) — 292KB
- kpti-20240826.xsd (EX-101.SCH) — 3KB
- kpti-20240826_lab.xml (EX-101.LAB) — 18KB
- kpti-20240826_pre.xml (EX-101.PRE) — 11KB
- d883504d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 10.1 Transition Agreement, dated as of August 29, 2024, between the Company and Michael Mason 10.2 Consulting Agreement, dated as of August 29, 2024, between the Company and Michael Mason 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: August 29, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary